Chris Gemmiti, PhD
Vice President of Operations
Dr. Gemmiti has been active in the cell therapy field for more than 20 years, including roles at Wyss Institute at Harvard University and Organogenesis Inc. At Organogenesis, he led the Oral Regeneration business unit’s cross-functional, strategic alignment for the clinical development, regulatory submission-and-review and commercial launch of GINTUIT™, the first manufactured allogeneic cell therapy approved by BLA (2012). He holds a PhD in Biomedical Engineering from Georgia Institute of Technology and a BS in both Biomedical Engineering and Engineering Mechanics from Johns Hopkins University. At Georgia Tech, Dr. Gemmiti was an NSF Fellow in Entrepreneurship through the TI:GER Program. Dr. Gemmiti has served on the Advisory Boards of the Institute for Bioengineering and Bioscience (Georgia Tech), Biomedical Engineering (Johns Hopkins and Duke University), Tissue Engineering and Regenerative Medicine International Society (TERMIS) and Cell Therapy Bioprocessing. He is also on the Board of Directors for the Children’s Museum in Easton (MA).